Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis

Ricevuti, G; Mazzone, A; Uccelli, E; Gazzani, G; Fregnan, G B
August 1988
Thorax;Aug1988, Vol. 43 Issue 8, p585
Academic Journal
No abstract available.


Related Articles

  • Chronic bronchitis: is bacteriological examination of sputum necessary? Peterson, I.C.; Petrie, G.R.; Crompton, G.K. // British Medical Journal;8/19/1978, Vol. 2 Issue 6136, p537 

    Assesses the necessity of routine bacteriological examination of purulent sputum for the management of infective exacerbations of chronic bronchitis. Performance of chemotherapy to patients; Conversion of sputum from purulent to mucoid; Valuability of specimen examination.

  • Oral Mucolytics Provide Benefits in Chronic Bronchitis. Walling, Anne D. // American Family Physician;12/15/2001, Vol. 64 Issue 12, p2000 

    Presents information from a study by P.J. Poole and P.N. Black to determine the potential benefits of mucolytic therapy for the treatment of chronic bronchitis. Description of the study and its results; Conclusion that regular use of mucolytic agents modestly reduces exacerbations and the...

  • Review: Mucolytic drugs reduce exacerbations, illness days, and antibiotic use in chronic bronchitis and COPD. Wiedemann, Herbert P. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p54 

    Presents information on a study which investigated the effectiveness of mucolytic drugs for reducing exacerbations or days of illness in patients with chronic bronchitis or chronic obstructive pulmonary disease. Methodology of the study; Results; Comments on the outcome of the study.

  • LUNG ALERT: ambroxol and reduction of COPD exacerbations. Perera, W. R. // Thorax;Apr2004, Vol. 59 Issue 4, p336 

    This study examined the effect of ambroxol in preventing acute exacerbations of Chronic Obstrctive Pulmonary Diseases (COPD). 242 patients with at least a history of chronic bronchitis, abnormal chest auscultation and at least one exacerbation in the previous year were recruited and randomised...

  • mucolytic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p378 

    The article presents information on the respiratory agents called mucolytic. The drugs dissolve or break down mucus. They are used to reduce the viscosity of sputum in the upper airways and facilitate expectoration. They can be used to treat asthma and chronic bronchitis. They can also be used...

  • Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease. Poole, Phillippa J; Black, Peter N // BMJ: British Medical Journal (International Edition);05/26/2001, Vol. 322 Issue 7297, p1271 

    Conclusions: In chronic bronchitis and chronic obstructive pulmonary disease, treatment with mucolytics is associated with a reduction in acute exacerbations and days of illness. As these drugs have to be taken long term, they could be most useful in patients who have repeated, prolonged, or...

  • Rapid Noninvasive Diagnosis of Pneumocystis carlinii from Induced Liquefied Sputum. Zaman, Muhammad K.; Wooten, Oscar J.; Suprahmanya, Ballambettu; Ankobiah, William; Finch, Peter J.P.; Kamholz, Stephan L. // Annals of Internal Medicine;7/1/88, Vol. 109 Issue 1, p7 

    Studies the efficacy of using induced liquified sputum for the diagnosis of Pneumocystis carinii pneumonia in HIV-infected patients having bronchoscopy. Infestation of the alveolar lumen in the patients; Use of a jet nebulizer in producing sputum by deep coughing; Application of a mucolytic...

  • carbocisteine.  // Royal Society of Medicine: Medicines;2002, p138 

    This article presents information on the mucolytic drug carbocisteine. This drug is used to reduce the viscosity of sputum and thus acts as an expectorant in patients with disorders of the upper respiratory tract, such as chronic asthma and bronchitis. Administration is oral. This drug can...

  • Visclair.  // Royal Society of Medicine: Medicines;2002, p565 

    This article provides information on Visclair, a proprietary, non-prescription preparation of the mucolytic and expectorant mecysteine hydrochloride from Sinclair. This drug can be used to reduce the viscosity of sputum and thus facilitate expectoration in patients with chronic asthma or...

  • Chronic obstructive pulmonary disease: clinical signs and infections. Banning, Maggi // British Journal of Nursing;9/14/2006, Vol. 15 Issue 16, p874 

    Chronic obstructive pulmonary disease (COPD) is a pathological condition that involves excessive production of mucus, chronic cough and inflammatory changes leading to airway limitation. The most common cause of COPD is cigarette smoking. COPD can be categorized into either chronic bronchitis or...


Read the Article


Sign out of this library

Other Topics